×

Before you go!

Sign up for the FREE weekly email newsletter from the publishers of American Nurse Today. You’ll get breaking news features, exclusive investigative stories, and more — delivered to your inbox.

Sign up today!

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Clinical Topics

A study in Nursing Research finds that the Registered Nurse Readiness for Hospital Discharge Scale can be successfully used to identify medical-surgical patients at risk for potential unplanned return to hospital within 30 days.

Read more via Journals.lww.com . . .

July 2018 Vol. 13 No. 7

Quick action results in a positive outcome.
By Debra A. Hrelic, PhD, RNC

Takeaways:

In sepsis, tachycardia and tachypnea are a response to an increased metabolic rate and the body’s effort to sustain perfusion to the vital organs.
Chorioamnionitis is diagnosed when maternal fever is accompanied by a minimum . . .

June 2018 Vol. 13 No. 6

Quick action puts a patient on the path to recovery.
Takeaways:

Isopropyl alcohol poisoning is uncommon and resembles ethanol intoxication because both toxins affect the central nervous system.
People ingest isopropyl alcohol to become intoxicated (when traditional alcohols aren’t available) or to harm themselves.
The presence of an anion . . .

Insurance denial rates for direct-acting antiviral drugs used to treat hepatitis C are high—more than 50% for those with private insurance—according to a study in Open Forum Infectious Diseases. The drugs have been a game-changer in saving patients lives.

Read more via Penn Medicine News and . . .

On June 4, the U.S. Food and Drug Administration (FDA) approved Fulphila (pegfilgrastim-jmdb) as the first biosimilar to Neulasta (pegfilgrastim) to decrease the chance of infection as suggested by febrile neutropenia in patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence . . .

Most participants in clinical trials believe the benefits of broadly sharing person-level data outweigh the risks, according to a study in The New England Journal of Medicine.

Read more via Stanford Medicine News Center and access the study The New England Journal of Medicine . . .

People with a family history of alcohol use disorder (AUD) release more dopamine in the brain’s main reward center in response to the expectation of alcohol than people diagnosed with the disorder, or healthy people without any family history of AUD, according to a study in Biological Psychiatry: Cognitive . . .

On May 11, the U.S. Food and Drug Administration (FDA) approved Gilenya (fingolimod) to treat relapsing multiple sclerosis (MS) in children and adolescents age 10 years and older. This is the first drug FDA has approved for treating MS in pediatric patients.

Read more via FDA.gov . . .

On May 15, the U.S. Food and Drug Administration (FDA) approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection.

Read more via FDA.gov . . .

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing